TRAPS is due to a mutation in the gene encoding one of two cellular receptors for one of the most important pro-inflammatory cytokines, TNF. The disease is characterized by long bouts of fever (several weeks) associated with abdominal pain, arthromyalgia, skin manifestations. These episodes reduce significantly the quality of life of subjects, significantly limiting the activities of daily living. The 15 to 25% of patients with renal amyloid develops in time progression to renal failure. Disease control requires the use of cortisone, which besides not being able to significantly change the course of the disease, exposes patients to side effects. The immunosuppressive drugs commonly used in inflammatory diseases have also proved ineffective. Treatment with biologic anti-TNF and interleukin-1 receptor antagonist (anakinra) are proven effective in significantly reducing the frequency and intensity symptoms.
The real problem: the cost of treatment with biologics
A separate problem is the high cost of these therapies that imposed at the time of their entry into the manual therapy, the creation of a dedicated observational registry of the Ministry of Health in collaboration with the Italian Society of Rheumatology (ANTARES study). This study aims to assess the costs, security of employment and, ultimately, to identify the patient's "ideal candidate" for such therapies. For this reason, the Reference Centres have been identified in each region for the management of these patients and data transmission to the Ministry.
For more information, please visit the sites listed below:
http://www.kineret-eu.com/italy/pro/abo/aboint.jsp
http://www.bresciareumatologia.it/biologici.html
0 comments:
Post a Comment